Phase 4 N=174 Randomized Single-blind Supportive Care

Block and Periarticular Injection Study

Pain, Postoperative

Bottom Line

View on ClinicalTrials.gov: NCT06410612 ↗

Enrolled (actual)

174

Serious AEs

0.0%

Results posted

Apr 2026

Primary outcome: Primary: Mean Visual Analog Scale (VAS) Pain Score for 2 Weeks Postoperatively — 3.41; 3.27 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: regional anesthesia and PAI (Drug); PAI (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Washington University School of Medicine
Primary completion: May 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Visual Analog Scale (VAS) Pain Score for 2 Weeks Postoperatively	3.41; 3.27	—
SECONDARY Opioid Use	16.75; 12.82	—
SECONDARY Daily Step Count at 2 Weeks Postop	3270.8; 3352.2	—
SECONDARY Oxford Knee Score	25.2; 25.6	—
SECONDARY Sleep Quality Via Survey That Patients Completed Ranging From Very Good Sleep and Fairly Good Sleep	26; 17	—
SECONDARY Oxford Knee Score	25.2; 25.6	—
SECONDARY Oxford Knee Score	25.2; 25.6	—
SECONDARY Sleep Quality Via App Surveys With Range of Very Good Sleep and Fairly Good Sleep	36; 32	—
SECONDARY Sleep Quality Via App Surveys With Range of Very Good Sleep to Fairly Good Sleep	41; 30	—

Summary

The purpose of the study is to compare two types of perioperative analgesic modalities, adductor canal block plus interspace between popliteal artery and capsule of the knee (IPACK) block and periarticular injection versus periarticular injection alone, to determine their relative efficacies with regard to pain relief and functional outcomes in the early postoperative period following primary total knee arthroplasty.

Eligibility Criteria

Inclusion Criteria

Planning to undergo Unilateral primary total knee arthroplasty.
18 and up
Willing to sign informed consent
Willing to return for all follow-up visits
Smartphone or tablet device capable of running the FocusMotion platform

Exclusion Criteria

BMI > 45
Preexisting functionally limiting neurologic disorders
Hepatic or renal insufficiency
History of unprovoked venous thromboembolism
Inability to complete baseline functional testing
Chronic opioid or gabapentin and pregabalin use (chronic defined as use >5 days per week prior to the surgical procedure)
Allergy or intolerance to trial medications
Planned admission to a postoperative rehabilitation facility
Planned general anesthesia
Receiving workers compensation or disability payments

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06410612). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.